Treatment outcomes for first therapy given after axi-cel progression
| Therapy . | CR . | ORR . | Median PFS (95% CI), d . | Median OS (95% CI), d . |
|---|---|---|---|---|
| Checkpoint inhibitor based (n = 28*) | 18% | 46% | 88 (35-282) | 331 (168-477) |
| Chemotherapy (n = 17) | 12% | 18% | 51 (21-64) | 104 (51-231) |
| Lenalidomide based (n = 27) | 19% | 19% | 48 (33-84) | 139 (45-NE) |
| Radiation (n = 10) | 20% | 30% | 58 (20-149) | 220 (20-NE) |
| Therapy . | CR . | ORR . | Median PFS (95% CI), d . | Median OS (95% CI), d . |
|---|---|---|---|---|
| Checkpoint inhibitor based (n = 28*) | 18% | 46% | 88 (35-282) | 331 (168-477) |
| Chemotherapy (n = 17) | 12% | 18% | 51 (21-64) | 104 (51-231) |
| Lenalidomide based (n = 27) | 19% | 19% | 48 (33-84) | 139 (45-NE) |
| Radiation (n = 10) | 20% | 30% | 58 (20-149) | 220 (20-NE) |
NE, not evaluable.
Two patients received checkpoint inhibitors but did not have response data available.